Israel Englander’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-722,121
| Closed | -$28.7M | – | 5926 |
|
|
2026
Q1 | $28.7M | Sell |
722,121
-1,148,550
| -61% | -$29.4M | 0.01% | 1268 |
|
|
2025
Q4 | $46.8M | Buy |
1,870,671
+968,403
| +107% | +$24.5M | 0.02% | 867 |
|
|
2025
Q3 | $21.9M | Sell |
902,268
-755,619
| -46% | -$13.4M | 0.01% | 1571 |
|
|
2025
Q2 | $21.8M | Buy |
1,657,887
+1,048,699
| +172% | +$13.3M | 0.01% | 1496 |
|
|
2025
Q1 | $8.76M | Buy |
609,188
+210,737
| +53% | +$3.45M | ﹤0.01% | 2322 |
|
|
2024
Q4 | $6.67M | Buy |
398,451
+168,072
| +73% | +$2.78M | ﹤0.01% | 2559 |
|
|
2024
Q3 | $3.68M | Buy |
230,379
+180,894
| +366% | +$2.22M | ﹤0.01% | 3115 |
|
|
2024
Q2 | $447K | Sell |
49,485
-237,908
| -83% | -$2.26M | ﹤0.01% | 4659 |
|
|
2024
Q1 | $3.25M | Buy |
287,393
+244,906
| +576% | +$2.32M | ﹤0.01% | 3294 |
|
|
2023
Q4 | $338K | Buy |
+42,487
| New | +$285K | ﹤0.01% | 4904 |
|
|
2021
Q4 | – | Sell |
-337,002
| Closed | -$5.63M | – | 6868 |
|
|
2021
Q3 | $5.63M | Sell |
337,002
-211,450
| -39% | -$4.38M | ﹤0.01% | 2734 |
|
|
2021
Q2 | $12.2M | Buy |
+548,452
| New | +$12.9M | 0.01% | 1681 |
|
Israel Englander's CNTA Position: Q2 2026 in Review
Israel Englander sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 722,121 shares — an estimated $28.7M sold.
Israel Englander first reported a position in CNTA in Q2 2021 and held it in 12 quarters. The position peaked at $46.8M in Q4 2025. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Israel Englander reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Israel Englander sold 722,121 Centessa Pharmaceuticals shares in Q2 2026, an estimated $28.7M.
- Israel Englander first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 12 quarters.
- Israel Englander's Centessa Pharmaceuticals position peaked at $46.8M in Q4 2025.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.